Christian Benden

Christian Benden

Auto-generated profile, based on publicly available information

Christian Benden

University of Zurich, Switzerland; Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MCMaria M. Crespo
Maria M. Crespo
DMDaniel P. McCarthy
Daniel P. McCarthy
PHPeter M. Hopkins
Peter M. Hopkins
SCStephen Clark
Stephen Clark
MBMarie Budev
Marie Budev
MMMichael Mulligan
Michael Mulligan

1 May 2020 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
SKSiddhartha G. Kapnadak
Siddhartha G. Kapnadak
EDEmily Dimango
Emily Dimango
DHDenis Hadjiliadis
Denis Hadjiliadis
SHSarah E. Hempstead
Sarah E. Hempstead
ETErin Tallarico
Erin Tallarico
RSRichard H. Simon
Richard H. Simon
Advanced cystic fibrosis lung disease (ACFLD) is common, is associated with reduced quality of life, and remains the most frequent cause of death in individuals with cystic fibrosis (CF). These consensus guidelines provide recommendations to the CF community on management of both common and unique issues that arise when individuals reach a state of ACFLD. The CF Foundation assembled a multidisciplinary expert panel consisting of three workgroups: Pulmonary management; Management of comorbid conditions; Symptom management and psychosocial issues. Topics were excluded if the management considerations did not differ in ACFLD from in the overall CF population or if already addressed in other published guidelines. Recommendations were based on a systematic literature review combined with expert opinion when appropriate. The committee formulated twenty-three recommendation statements specific to ACFLD that address the definition of ACFLD, pulmonary and intensive care unit management, management of selected comorbidities, symptom control, and psychosocial issues. These recommendations are intended to be paired with previously published management guidelines for the overall CF population, with the objective of reducing practice variability and improving overall care, quality of life, and survival in those with ACFLD.

1 September 2017 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
CBChristian Benden
Christian Benden
MHMaria Haughton
Maria Haughton
SLSaoirse Leonard
Saoirse Leonard
LHLars C. Huber
Lars C. Huber

25 July 2022 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
AGAllan R. Glanville
Allan R. Glanville
CBChristian Benden
Christian Benden
ABAnne Bergeron Bergeron
Anne Bergeron Bergeron
GCGuang-Shing Cheng
Guang-Shing Cheng
JGJens Gottlieb
Jens Gottlieb
GVGeert M. Verleden
Geert M. Verleden
Bronchiolitis obliterans syndrome (BOS) may develop after either lung or haematopoietic stem cell transplantation (HSCT), with similarities in histopathological features and clinical manifestations. However, there are differences in the contributory factors and clinical trajectories between the two conditions. BOS after HSCT occurs due to systemic graft-versus-host disease (GVHD), whereas BOS after lung transplantation is limited to the lung allograft. BOS diagnosis after HSCT is more challenging, as the lung function decline may occur due to extrapulmonary GVHD, causing sclerosis or inflammation in the fascia or muscles of the respiratory girdle. Treatment is generally empirical with no established effective therapies. This review provides rare insights and commonalities of both conditions, which are not well elaborated elsewhere in contemporary literature, and highlights the importance of cross disciplinary learning from experts in other transplant modalities. Treatment algorithms for each condition are presented, based on the published literature and consensus clinical opinion. Immunosuppression should be optimised, and other conditions or contributory factors treated where possible. When initial treatment fails, the ultimate therapeutic option is lung transplantation (or re-transplantation in the case of BOS after lung transplantation) in carefully selected candidates. Novel therapies under investigation include aerosolised liposomal cyclosporine, Janus kinase inhibitors, antifibrotic therapies and (in patients with BOS after lung transplantation) B-cell-directed therapies. Effective novel treatments that have a tangible impact on survival and thereby avoid the need for lung transplantation or re-transplantation are urgently required.

10 March 2022 in Clinical Transplantation
Verified
Journal Article
Closed access
NANicholas Avdimiretz
Nicholas Avdimiretz
CBChristian Benden
Christian Benden

1 August 2017 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
CBChristian Benden
Christian Benden
Pediatric lung transplantation has been undertaken since the 1980s, and it is today considered an accepted therapy option in carefully selected children with end-stage pulmonary diseases, providing carefully selected children a net survival benefit and improved health-related quality of life. Nowadays, >100 pediatric lung transplants are done worldwide every year. Here, specific pediatric aspects of lung transplantation are reviewed such as the surgical challenge, effects of immunosuppression on the developing pediatric immune system, and typical infections of childhood, as it is vital to comprehend that children undergoing lung transplants present a real challenge as children are not ‘just small adults’. Further, an update on the management of the pediatric lung transplant patient is provided in this review, and future challenges outlined. Indications for lung transplantation in children are different compared to adults, the most common being cystic fibrosis (CF). However, the primary diagnoses leading to pediatric lung transplantation vary considerably by age group. Furthermore, there are regional differences regarding the primary indication for lung transplantation in children. Overall, early referral, careful patient selection and appropriate timing of listing are crucial to achieve real survival benefit. Although allograft function is to be preserved, immunosuppressant-related side effects are common in children post-transplantation. Strategies need to be put into practice to reduce drug-related side effects through careful therapeutic drug monitoring and lowering of target levels of immunosuppression, to avoid acute-reversible and chronic-irreversible renal damage. Instead of a “one fits all approach”, tailored immunosuppression and a personalized therapy is to be advocated, particularly in children. Further, infectious complications are a common in children of all ages, accounting for almost 50% of death in the first year post-transplantation. However, chronic lung allograft dysfunction (CLAD) remains the major obstacle for improved long-term survival.